Loading
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Latest filing published 12 Oct 2010 for ZYMOGENETICS INC, €28k.
Insider track record
Disclosed buys
9
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
9
Positive at T+90
25%
Median T+90
-44.5%
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +157.1%Entry US$1.40 · Close at T+365 US$3.60
- -35.8%Entry US$3.88 · Close at T+365 US$2.49
- -79.8%Entry US$5.29 · Close at T+365 US$1.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
James A. Harper: trading record in brief
This profile gathers the share dealings of James A. Harper across 3 companies, led by Corcept Therapeutics Inc, Corgentech Inc and Zymogenetics Inc. The record holds 10 filings, for trades running from 10 March 2006 to 8 October 2010.
No open-market sale appears; the market trades are 9 purchases worth €146k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
A typical purchase (the median) is worth €8,777. Ninety days after publication, 4 purchases show a median change of -44.5%, with the price up in 25% of them. Past outcomes like these are no guarantee of what comes next.
The latest filing, published on 12 October 2010, reports a transaction of €28k in Zymogenetics Inc. The clock since the last published purchase (21 November 2007) now reads 6,911 days. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to James A. Harper
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
4,000 shares@ US$9.75Common StockSEC:0001209191-10-050016:0
2,411 shares@ US$5.40Common StockSEC:0001131517-07-000042:0
Canonical exit: 18 Feb 2008 (T+90)
4,818 shares@ US$5.50Common StockSEC:0001131517-07-000042:1
Canonical exit: 19 Feb 2008 (T+90)
1,801 shares@ US$5.50Common StockSEC:0001131517-07-000041:0
Canonical exit: 14 Feb 2008 (T+90)
1,801 shares@ US$5.50Common StockSEC:0001131517-07-000040:0
Canonical exit: 13 Feb 2008 (T+90)
4,000 shares@ US$12.80Common StockSEC:0001209191-07-047890:0
Canonical exit: 11 Nov 2007 (T+90)
50,000 shares@ US$1.00Common StockSEC:0001209191-07-022010:0
Canonical exit: 28 Jun 2007 (T+90)
600 shares@ US$4.05Common StockSEC:0001209191-06-039867:0
Canonical exit: 28 Sept 2006 (T+90)
1,800 shares@ US$4.15Common StockSEC:0001209191-06-039867:1
Canonical exit: 3 Oct 2006 (T+90)
5,500 shares@ US$4.91Common StockSEC:0001209191-06-017571:0
Canonical exit: 8 Jun 2006 (T+90)
10 of 10 declarations
